Photo taken from Anand Patel/X
Dec 15, 2023, 06:30
Anand Patel: Our poster (3192) on allo-HCT in MPN-AP/BP in the current era of myeloid therapies at ASH23
Quoting Anand Patel, Assistant Professor and Director of the Inpatient Leukemia Service at the University of Chicago, on X/Twitter:
“Our poster (3192) on allogeneic hematopoietic cell transplantation (allo-HCT) in Accelerated Phase of Myeloproliferative Neoplasms/Blast Phase (MPN-AP/BP) in the current era of myeloid therapies at the American Society of Hematology (ASH23).
-65 of 202 patients received allo-HCT.
-Median overall survival 2.3 years from the time of allo-HCT.
-No difference in overall survival based on first-line treatment for MPN-AP/BP or response prior to allo.”
Source: Anand Patel/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 20, 2024, 20:38
Nov 20, 2024, 20:27
Nov 20, 2024, 19:12
Nov 20, 2024, 19:12
Nov 20, 2024, 19:12
Nov 20, 2024, 19:12